The glucagon-like peptide-1 (GLP-1) receptor agonist market has evolved from a niche diabetes treatment category into the most lucrative pharmaceutical frontier of the century. Analysts now project global GLP-1 sales will exceed $150 billion by 2030, driven by an unprecedented surge in demand for obesity treatments. As the market expands, the competitive dynamics are shifting rapidly. What was once a duopoly dominated by Novo Nordisk is now being aggressively overtaken by Eli Lilly, while a new wave of emerging challengers races to develop the next generation of oral and monthly therapies.

The landscape is defined by two major inflection points in 2026: the rollout of oral GLP-1 pills and the introduction of Medicare coverage for obesity treatments in the United States. These catalysts will drive massive volume expansion, even as pricing pressures mount following the landmark agreements struck with the White House to slash drug costs. In this environment, pipeline superiority, manufacturing scale, and convenience will dictate the winners.

The Market Leaders: A Diverging Duopoly

The GLP-1 market is highly consolidated, with the top players controlling over 95% of the market share. However, the trajectories of the two dominant forces—Eli Lilly and Novo Nordisk—are diverging sharply in 2026.

Eli Lilly (NYSE: LLY)

Eli Lilly has decisively captured the momentum in the GLP-1 space. The company recently became the first pharmaceutical firm to reach a $1 trillion market capitalization, fueled by the explosive growth of its tirzepatide franchise (Mounjaro for diabetes and Zepbound for obesity). In 2025, combined sales for these two drugs reached $36.5 billion, making tirzepatide the world’s best-selling drug.

Lilly’s dominance is underpinned by clinical superiority. Tirzepatide has proven more effective than Novo Nordisk’s semaglutide in head-to-head trials, driving a clear preference among prescribers. Furthermore, Lilly’s 2026 financial guidance projects revenue between $80 billion and $83 billion—a 25% increase at the midpoint—defying the pricing headwinds that have hampered its primary rival.

The company’s pipeline ensures its leadership will extend well into the next decade. Retatrutide, Lilly’s investigational triple-hormone-receptor agonist (targeting GLP-1, GIP, and glucagon), is demonstrating unprecedented efficacy. Phase 3 TRIUMPH-1 data revealed an average weight loss of 28.3% over 80 weeks, with 45.3% of participants achieving 30% or greater weight reduction, setting a new benchmark for the industry. Additionally, Lilly’s oral small molecule GLP-1, orforglipron, is poised for FDA approval in the second quarter of 2026. Unlike peptide-based pills, orforglipron requires no dietary restrictions, offering a significant convenience advantage over Novo Nordisk’s oral Wegovy.

Verdict: BUY

Price Target: $1,250.00

Eli Lilly is the undisputed king of the metabolic space. Its superior clinical data, robust pipeline (retatrutide and orforglipron), and aggressive direct-to-consumer pricing strategies make it a core holding for any healthcare portfolio. The stock trades at approximately $1,130 as of early June 2026, offering meaningful upside to our target.

Novo Nordisk (NYSE: NVO)

Novo Nordisk effectively created the modern obesity market with Wegovy, but the Danish giant is now playing defense. The company recently issued a stark warning that 2026 sales and profits could decline by 5% to 13%, citing severe pricing pressures in the U.S. and patent expirations in key international markets like China, Brazil, and Canada. This guidance triggered a massive 20% drop in its share price.

Despite these headwinds, Novo Nordisk remains a formidable competitor. The company’s semaglutide franchise generated $33 billion in 2025. Novo was also first to market with an oral GLP-1 pill for obesity, which saw rapid initial uptake of 50,000 weekly prescriptions within three weeks of launch. However, its pipeline has encountered stumbling blocks. CagriSema, a highly anticipated combination of cagrilintide and semaglutide, demonstrated strong weight loss of 14.2% in Phase 3 trials but was bested by Lilly’s Zepbound in a head-to-head study, where Zepbound achieved 16.48% weight loss.

The bright spot in Novo’s pipeline is amycretin, a novel unimolecular GLP-1 and amylin receptor agonist. Early Phase 2 data showed promising weight loss of 13.1% for the oral formulation and an impressive 24.3% for the injectable version, positioning it as a strong future contender. Novo has advanced amycretin to Phase 3 development.

Verdict: HOLD

Price Target: $58.00

Novo Nordisk’s near-term outlook is clouded by pricing pressures and market share losses to Eli Lilly. While the stock’s recent pullback to approximately $43 presents a more attractive valuation, investors should wait for clearer signs of pipeline execution—particularly regarding amycretin—before initiating new positions. The stock offers approximately 35% upside to our target, but execution risk remains elevated.

The Emerging Challengers

As the GLP-1 market expands toward $150 billion in annual sales, a cohort of biotechnology and pharmaceutical companies are developing differentiated therapies aimed at carving out lucrative niches. These challengers are focusing on less frequent dosing, improved tolerability, and oral administration.

Amgen (NASDAQ: AMGN)

Amgen is taking a unique approach with MariTide (maridebart cafraglutide), a bispecific molecule that activates the GLP-1 receptor while blocking the GIP receptor. The drug’s primary competitive advantage is its dosing schedule: it is the first monthly obesity treatment in late-stage development. Phase 2 data demonstrated up to 20% average weight loss over 52 weeks without hitting a plateau, suggesting the potential for further weight reduction beyond one year. Amgen is currently advancing the drug through its comprehensive Phase 3 MARITIME clinical program, which includes a 72-week study testing multiple doses. If approved, the convenience of a monthly injection could capture a significant segment of the market that suffers from injection fatigue with weekly dosing regimens.

Verdict: BUY

Price Target: $390.00

Amgen offers a compelling risk-reward profile at its current price near $345. MariTide’s differentiated mechanism and monthly dosing schedule provide a strong moat against the weekly injections dominating the market today. The company’s established commercial infrastructure and manufacturing expertise further de-risk execution.

Viking Therapeutics (NASDAQ: VKTX)

Viking Therapeutics has emerged as one of the most closely watched clinical-stage biotechs in the obesity space. The company’s dual GLP-1/GIP agonist, VK2735, delivered highly impressive Phase 2 results in the VENTURE trial, showing 14.7% weight loss in just 13 weeks with no signs of a plateau. Viking is advancing both subcutaneous and oral formulations of the drug. With a market capitalization hovering around $3.5 billion and no current revenue, Viking is widely considered a prime acquisition target for larger pharmaceutical companies looking to enter or expand their presence in the obesity market.

Verdict: BUY

Price Target: $95.00

Viking is a high-conviction speculative play. Trading near $30, the stock offers substantial upside to our $95 target. The clinical data for VK2735 is robust enough to validate the asset, making the company an attractive buyout candidate or a formidable standalone player in the long term. Investors should size positions appropriately given the binary risk profile inherent to clinical-stage companies.

Structure Therapeutics (NASDAQ: GPCR)

Structure Therapeutics is developing aleniglipron, an oral small molecule GLP-1 receptor agonist that has demonstrated best-in-class efficacy among oral candidates. The company recently reported highly positive Phase 2 ACCESS II data, showing a placebo-adjusted mean weight loss of 16.3% at 44 weeks with no evidence of a weight loss plateau. Crucially, aleniglipron boasts a very low discontinuation rate due to adverse events (around 2% to 3.4% with the optimized 2.5 mg starting dose), addressing one of the primary challenges of the GLP-1 class. The company has an End-of-Phase 2 meeting with the FDA scheduled in Q2 2026 and plans to initiate Phase 3 trials in the second half of 2026.

Verdict: BUY

Price Target: $110.00

Structure Therapeutics has the most promising oral small molecule in development outside of Eli Lilly. Trading near $38, the stock offers nearly 3x upside to our target. Its best-in-class efficacy and tolerability profile make it a standout among the emerging challengers. The company is also a potential acquisition target for larger pharma companies seeking oral obesity assets.

Roche Holding AG (OTC: RHHBY)

Roche entered the obesity race late via its $2.7 billion acquisition of Carmot Therapeutics. The company is advancing CT-388, a weekly injectable GLP-1/GIP dual agonist that showed 22.5% weight loss (placebo-adjusted 18.3%) at 48 weeks in Phase 2 trials. Roche plans to advance CT-388 into Phase 3 testing and is also developing an oral candidate, CT-996, which demonstrated 7.3% weight loss in just four weeks of Phase 1 testing. While the data is competitive, Roche is years behind Lilly and Novo Nordisk in commercialization. The company will need to demonstrate a clear path to commercial relevance in an increasingly crowded field.

Verdict: HOLD

Price Target: $57.00

Roche’s pipeline assets are solid, but the company’s late entry into the obesity market limits its upside potential in this space. Trading near $51.50, the stock offers modest upside to our target. Roche remains a hold based on its broader oncology and diagnostics portfolio, with obesity representing an optionality play rather than a near-term growth driver.

Pfizer (NYSE: PFE)

Pfizer serves as a cautionary tale in the GLP-1 arms race. The company officially discontinued the development of its oral GLP-1 candidate, danuglipron, in April 2025 due to drug-induced liver injury concerns. This failure effectively removed Pfizer from the obesity competition, highlighting the immense difficulty of developing safe and effective small molecule GLP-1 therapies. The company must now rely on its legacy portfolio, COVID-19 franchise wind-down, and newer oncology acquisitions (including the Seagen deal) to drive growth.

Verdict: HOLD

Price Target: $30.00

With its obesity pipeline decimated, Pfizer must rely on its oncology portfolio and cost-cutting initiatives to drive shareholder value. The stock lacks the near-term catalysts necessary to justify a buy rating in the context of the GLP-1 opportunity.

Summary of Ratings and Price Targets

Company	Ticker	Current Price	Rating	Price Target
Eli Lilly	LLY	~$1,130	BUY	$1,250.00
Novo Nordisk	NVO	~$43	HOLD	$58.00
Amgen	AMGN	~$345	BUY	$390.00
Viking Therapeutics	VKTX	~$30	BUY	$95.00
Structure Therapeutics	GPCR	~$38	BUY	$110.00
Roche Holding	RHHBY	~$51.50	HOLD	$57.00
Pfizer	PFE	~$26	HOLD	$30.00

Conclusion

The GLP-1 market is undergoing a structural transformation that will reshape the pharmaceutical industry for decades to come. Eli Lilly has firmly established itself as the apex predator, leveraging superior clinical data and aggressive commercial strategies to outmaneuver Novo Nordisk. The TRIUMPH-1 data for retatrutide—showing 28.3% weight loss—represents a quantum leap in efficacy that will further entrench Lilly’s dominance.

Meanwhile, emerging players like Amgen, Viking Therapeutics, and Structure Therapeutics are developing highly differentiated therapies that promise to reshape the treatment paradigm with monthly injections and best-in-class oral pills. For investors, the obesity sector remains a generational wealth-creation opportunity, provided capital is allocated toward the companies with the most robust and convenient pipelines.

The key risk to monitor is pricing pressure. The White House agreements and Medicare coverage expansion will compress margins in the near term, but the massive expansion of the addressable patient population—from 20-25 million current patients to potentially 100 million or more—should more than offset lower per-unit economics. We remain overweight the GLP-1 sector and recommend investors build positions in Eli Lilly as a core holding, with satellite positions in Amgen, Viking Therapeutics, and Structure Therapeutics for differentiated exposure.

Disclaimer: This report is for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results. Investors should conduct their own due diligence before making investment decisions. Price targets reflect 12-month forward estimates based on current market conditions and pipeline expectations.